Xarelto (Rivaroxaban)
Indications
Rivaroxaban is the most broadly indicated direct oral anticoagulant in the United States, with ten distinct FDA-approved uses spanning stroke prevention in atrial fibrillation, treatment and secondary prevention of venous thromboembolism, post-orthopaedic and medical-patient prophylaxis, secondary prevention in chronic atherosclerotic disease, and paediatric VTE and post-Fontan thromboprophylaxis. The dosing varies substantially across indications, and the FDA prescribing information explicitly cautions against off-label use in prosthetic heart valves and triple-positive antiphospholipid syndrome.
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Stroke and systemic embolism prevention in nonvalvular atrial fibrillation (NVAF) | Adults with NVAF | Monotherapy | FDA Approved |
| Treatment of deep vein thrombosis (DVT) | Adults with acute DVT | Monotherapy (no parenteral lead-in required) | FDA Approved |
| Treatment of pulmonary embolism (PE) | Adults with acute PE (haemodynamically stable) | Monotherapy (no parenteral lead-in required) | FDA Approved |
| Reduction in risk of recurrence of DVT and/or PE | Adults at continued risk after ≥6 months of standard anticoagulation | Extended secondary prevention | FDA Approved |
| Prophylaxis of DVT after hip or knee replacement surgery | Adult orthopaedic surgery patients | Postoperative prophylaxis | FDA Approved |
| Prophylaxis of VTE in acutely ill medical patients | Hospitalised medical patients with restricted mobility, not at high bleeding risk | In-hospital and post-discharge prophylaxis (31–39 days) | FDA Approved |
| Reduction of risk of major CV events in coronary artery disease (CAD) | Adults with chronic CAD | Combination with low-dose aspirin (vascular dose 2.5 mg BID) | FDA Approved |
| Reduction of risk of major thrombotic vascular events in PAD, including post-LER | Adults with PAD, including patients post-lower extremity revascularisation | Combination with low-dose aspirin (vascular dose 2.5 mg BID) | FDA Approved |
| Treatment and reduction of recurrence of VTE in paediatric patients | Birth to <18 years; after ≥5 days of parenteral anticoagulation | Weight-based oral suspension or tablets | FDA Approved |
| Thromboprophylaxis after Fontan procedure | Paediatric patients ≥2 years with congenital heart disease post-Fontan | Weight-based oral suspension or tablets | FDA Approved |
| Cancer-associated thrombosis (CAT) treatment | Adults with active malignancy and acute VTE | Monotherapy (no specific FDA CAT indication; CHEST and ASH guidelines endorse selected patients) | Off-label |
| Cerebral or splanchnic vein thrombosis | Adults with confirmed thrombosis at unusual sites | Monotherapy (off-label; growing observational data) | Off-label |
The pivotal evidence supporting these indications spans more than ten randomised trials. ROCKET-AF (Patel 2011) established non-inferiority to dose-adjusted warfarin for stroke prevention in 14,264 NVAF patients; EINSTEIN-DVT and EINSTEIN-PE (2010, 2012) established single-drug oral therapy for acute VTE without parenteral lead-in; EINSTEIN-CHOICE (Weitz 2017) supported the 10 mg extended-prevention dose; the RECORD program (1–3) established 10 mg once daily for orthopaedic prophylaxis; MAGELLAN (Cohen 2013) supported extended prophylaxis in acutely ill medical patients (with caveats around bleeding-risk subgroups now excluded from labelling); and COMPASS (Eikelboom 2017) and VOYAGER PAD (Bonaca 2020) established the vascular dose of 2.5 mg BID with aspirin for chronic CAD and PAD respectively.
• Mechanical heart valves and TAVR: the GALILEO trial showed higher rates of death and bleeding with rivaroxaban after transcatheter aortic valve replacement; rivaroxaban is not recommended in patients with prosthetic heart valves.
• Triple-positive antiphospholipid syndrome: direct-acting oral anticoagulants (DOACs), including rivaroxaban, are associated with increased recurrent thrombotic events compared with vitamin K antagonists in this population.
• Haemodynamically unstable PE or patients requiring thrombolysis or pulmonary embolectomy: not recommended as initial therapy in place of unfractionated heparin.
• Acutely ill medical patients at high bleeding risk: excluded from MAGELLAN labelling (history of bronchiectasis or pulmonary cavitation, active cancer with in-hospital treatment, dual antiplatelet therapy, recent gastroduodenal ulcer or recent bleeding).
Dosing
Rivaroxaban dosing varies by indication, renal function, and food-coadministration requirements. The 15 mg and 20 mg doses must be taken with food; the 2.5 mg and 10 mg doses can be taken with or without food. The FDA-approved labelling avoids use in CrCl <15 mL/min for VTE-related indications; for NVAF, 15 mg once daily is used in CrCl 15–50 mL/min.
| Indication | Loading / Initiation | Maintenance Dose | Duration | Notes |
|---|---|---|---|---|
| NVAF, CrCl >50 mL/min | None | 20 mg PO once daily | Long-term | Take with the evening meal Food increases AUC of 20 mg dose by ~39% and Cmax by ~76% |
| NVAF, CrCl 15–50 mL/min | None | 15 mg PO once daily | Long-term | Take with the evening meal For ESRD on dialysis, 15 mg daily expected to give similar exposure to ROCKET-AF (clinical outcomes not established) |
| Treatment of acute DVT or PE, CrCl ≥15 mL/min | None — oral monotherapy | 15 mg PO BID for 21 days → 20 mg PO once daily | Typically ≥3–6 months | Take all doses with food Avoid in CrCl <15 mL/min |
| Reduction of recurrent DVT/PE risk | After ≥6 months of standard anticoagulation | 10 mg PO once daily | Continued indefinitely while risk persists | With or without food; avoid in CrCl <15 mL/min EINSTEIN-CHOICE: 10 mg dose preferred over 20 mg for extended prevention (lower bleeding) |
| Hip replacement prophylaxis, CrCl ≥15 mL/min | 6–10 h after surgery, once haemostasis established | 10 mg PO once daily | 35 days | With or without food |
| Knee replacement prophylaxis, CrCl ≥15 mL/min | 6–10 h after surgery, once haemostasis established | 10 mg PO once daily | 12 days | With or without food |
| VTE prophylaxis in acutely ill medical patients | None | 10 mg PO once daily | 31–39 days total (in-hospital plus post-discharge) | Exclude high-bleeding-risk subgroups (see Indications callout) |
| Chronic CAD or PAD — vascular dose | None | 2.5 mg PO BID + ASA 75–100 mg daily | Long-term while net benefit favourable | With or without food No CrCl-based dose adjustment for CAD/PAD; limited data in CrCl 15–30 mL/min |
| Post-LER for symptomatic PAD | Initiate after haemostasis established post-procedure | 2.5 mg PO BID + ASA 75–100 mg daily | Long-term per VOYAGER PAD | With or without food |
| Paediatric VTE (birth to <18 yr) | After ≥5 days of parenteral anticoagulation | Weight-based; see PI Table 2 (oral suspension 1 mg/mL or tablet) | ≥3 months (1 month minimum if <2 yr with catheter-related VTE) | Take all doses with feeding/food Avoid in eGFR <50 mL/min/1.73 m² or hepatic impairment |
| Paediatric Fontan thromboprophylaxis (≥2 yr) | None | Weight-based; see PI Table 3 | Long-term | Can be taken with or without food |
Special populations
| Population | Adjustment | Rationale |
|---|---|---|
| CrCl <15 mL/min (non-dialysis) | Avoid use for VTE-related and orthopaedic indications | No clinical data; rivaroxaban exposure increased; bleeding risk likely higher |
| End-stage renal disease on haemodialysis (NVAF only) | 15 mg once daily is expected to give exposure similar to ROCKET-AF | PK modelling only; clinical efficacy and safety in dialysis patients not established |
| Moderate hepatic impairment (Child-Pugh B) | Avoid use | Rivaroxaban exposure and bleeding risk increased; safety not established |
| Severe hepatic impairment (Child-Pugh C) or hepatic disease with coagulopathy | Avoid use | No clinical data; coagulopathy already present |
| Geriatric (≥65 years) | No specific adjustment beyond renal dosing | Half-life prolonged to 11–13 h vs 5–9 h in younger adults; bleeding rates higher in absolute terms |
| Body weight extremes | No formal dose adjustment | Limited efficacy and bleeding data at body weight >120 kg or BMI >40 kg/m²; ISTH 2021 guidance describes DOAC use as acceptable in obesity for some indications but with cautions |
| Pregnancy and lactation | Avoid use unless benefit clearly outweighs risk | Crosses placenta in animal studies; detected in human breast milk; LMWH preferred during pregnancy |
| Switching from warfarin to rivaroxaban | Start when INR <3.0 (adults) or <2.5 (paediatric) | Avoid periods of inadequate anticoagulation |
| Switching from rivaroxaban to warfarin (adults) | Discontinue rivaroxaban and bridge with parenteral anticoagulant + warfarin | INR is unreliable during rivaroxaban co-administration |
| Switching to/from non-warfarin anticoagulants | Give first dose of new agent at time of next scheduled rivaroxaban dose | Maintains continuous anticoagulation given the rapid onset/offset of DOACs |
• Food matters for 15 and 20 mg doses. Fasted bioavailability of the 20 mg dose is only ~66%; food increases AUC by ~39% and Cmax by ~76%. Counsel patients to take the dose with the largest meal of the day to minimise variability.
• Discontinue at least 24 hours before invasive procedures with bleeding risk. Some bleeding-risk procedures may need a longer interval (48 h or more) particularly in CrCl 15–50 mL/min.
• Premature discontinuation increases thrombotic events (boxed warning). If stopping for any reason other than bleeding or end of therapy, bridge with another anticoagulant.
• Tablets can be crushed and mixed with applesauce or suspended in water for feeding-tube administration. The 15 and 20 mg crushed doses must be followed by enteral feeding to ensure absorption.
• Avoid administration distal to the stomach (e.g. jejunostomy tubes) — absorption is significantly reduced.
• Routine coagulation monitoring is not needed. Anti-factor Xa activity (rivaroxaban-calibrated) is the most useful test if quantification is needed in bleeding, urgent surgery, or suspected non-adherence.
Pharmacology
Mechanism of Action
Rivaroxaban is a selective, reversible, direct inhibitor of activated factor X (factor Xa). It binds free factor Xa as well as factor Xa within the prothrombinase complex without requiring antithrombin as a cofactor — a key difference from heparins and fondaparinux. By blocking factor Xa, rivaroxaban inhibits thrombin generation and downstream fibrin formation, producing a predictable, dose-dependent anticoagulant effect. It has no direct effect on platelet aggregation, but indirectly reduces thrombin-mediated platelet activation. Onset is rapid: peak plasma concentrations occur within 2–4 hours and peak anti-factor Xa activity tracks closely with plasma drug levels. The PT, INR, and aPTT are dose-dependently prolonged but are not reliable for therapeutic monitoring.
ADME profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | 2.5/10 mg: 80–100% bioavailable, food-independent. 20 mg: 66% fasted; with food AUC increases by ~39% and Cmax by ~76%; Tmax 2–4 h | 15 and 20 mg tablets must be taken with food; absorption decreases markedly if drug is released distal to stomach |
| Distribution | ~92–95% bound to plasma protein (mainly albumin); steady-state Vd ~50 L | Not effectively dialysable due to high protein binding; modest tissue distribution |
| Metabolism | Hepatic CYP3A4/5 (~18%) and CYP2J2 (~14%); plus ~14% via CYP-independent hydrolysis of amide bonds. Substrate of P-gp and BCRP transporters | Combined P-gp + strong CYP3A inhibitors (ketoconazole, ritonavir) raise exposure significantly — avoid use; combined inducers (rifampin, carbamazepine) reduce exposure — avoid use |
| Elimination | Terminal t½ 5–9 h in young adults, 11–13 h in elderly. ~36% excreted unchanged in urine (via glomerular filtration plus active tubular secretion); ~7% unchanged in faeces; remainder as inactive metabolites | Renal impairment increases exposure ~44–64%; significant dose adjustments required for VTE indications; use caution in elderly |
The 2.5 mg twice-daily “vascular dose” tested in COMPASS and VOYAGER PAD is roughly one-quarter of the standard NVAF dose. At this exposure, rivaroxaban achieves partial factor Xa inhibition that — combined with low-dose aspirin — produces additive antithrombotic benefit on the arterial side without the bleeding penalty of full-dose anticoagulation. COMPASS reported a 24% relative reduction in CV death/MI/stroke (4.1% vs 5.4% with aspirin alone) at the cost of a hazard ratio of 1.8 for modified ISTH major bleeding (1.6%/yr vs 0.9%/yr). The 2.5 mg dose is not effective for stroke prevention in AF or for VTE treatment.
Side Effects
Bleeding is by far the most common adverse reaction across all rivaroxaban indications and is the most frequent cause of treatment discontinuation. Frequencies vary substantially by trial and clinical setting; rates below are drawn from the FDA prescribing information and the original pivotal trials. The principal non-haemorrhagic adverse reactions are mild (back pain, dizziness, pruritus, abdominal pain, fatigue) and generally do not require discontinuation.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Any bleeding (EINSTEIN DVT/PE pooled) | 28.3% vs 28.0% enoxaparin/VKA | Includes nuisance bleeding (epistaxis, gum bleeding, easy bruising) |
| Any bleeding (EINSTEIN-CHOICE 10 mg) | 13.4% vs 12.2% aspirin | Reflects long-term low-intensity exposure |
| Menorrhagia (paediatric ≥12 yr who reached menarche, EINSTEIN Junior) | 27% vs 10% comparator | Counsel adolescent female patients; tranexamic acid or hormonal options may help |
| Cough (paediatric Fontan, UNIVERSE) | 15.6% vs 8.8% aspirin | Generally mild; assess for other causes if persistent |
| Vomiting (paediatric VTE, EINSTEIN Junior) | 10.6% vs 8.0% comparator | Re-administer dose if vomiting occurs within 30 min |
| Gastroenteritis (paediatric Fontan) | 12.5% vs 2.9% aspirin | Combined viral and non-viral; generally self-limiting |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Clinically relevant non-major bleeding (EINSTEIN DVT/PE) | 8.6% vs 8.7% | Most common cause of dose interruption in VTE treatment |
| Any bleeding (RECORD 1-3 hip/knee) | 5.8% vs 5.6% enoxaparin | Most occur in the first postoperative week |
| NVAF major bleeding (ROCKET-AF) | 3.6%/yr vs 3.5%/yr warfarin | Numerically similar to warfarin overall but with different anatomical pattern |
| Pediatric “trivial bleeding” (EINSTEIN Junior) | 34.3% vs 27.2% comparator | Includes minor mucocutaneous bleeding not requiring intervention |
| CRNM bleeding (MAGELLAN) | 2.9% vs 1.1% enoxaparin/placebo | Higher with rivaroxaban in extended prophylaxis setting |
| Wound secretion (RECORD post-orthopaedic) | 2.8% vs 2.0% enoxaparin | Surgical site oozing or discharge; usually self-limiting |
| Back pain (EINSTEIN DVT) | 2.9% vs 1.8% enoxaparin/VKA | Investigate to rule out retroperitoneal bleed if severe |
| Abdominal pain (EINSTEIN DVT) | 2.7% vs 1.5% | Consider GI bleeding work-up if persistent |
| Pruritus (EINSTEIN PE; RECORD) | 2.2% vs 1.1%; 2.1% vs 1.8% | Usually mild; rule out drug rash if persistent |
| Dizziness (EINSTEIN DVT) | 2.2% vs 1.3% | Consider orthostatic vitals; rule out occult bleeding |
| GI bleeding (ROCKET-AF NVAF) | 2.0%/yr vs 1.2%/yr warfarin | Higher than warfarin; PPI may be considered in high-risk patients |
| Major CV-disease bleeding (COMPASS, modified ISTH) | 1.6%/yr vs 0.9%/yr placebo (HR 1.8) | Vascular dose plus aspirin vs aspirin alone |
| TIMI major bleeding (VOYAGER PAD) | 1.9% vs 1.4% placebo (HR 1.4) | Principally GI bleeding |
| Major bleeding (EINSTEIN DVT/PE pooled) | 1.0% vs 1.7% enoxaparin/VKA | Lower than VKA in acute VTE treatment |
| Pain in extremity, muscle spasm, syncope (RECORD) | 1.7%, 1.2%, 1.2% | Higher than enoxaparin in postoperative orthopaedic setting |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Major bleeding (any indication) | 0.3% (post-op) to 3.6%/yr (NVAF) | Throughout therapy | Hold rivaroxaban; assess severity; consider andexanet alfa or 4F-PCC if life-threatening |
| Intracranial haemorrhage | 0.5%/yr (ROCKET-AF) — lower than warfarin (HR 0.67) | Any time | Permanent discontinuation; emergency neuroimaging; reverse with andexanet alfa; neurosurgery consult |
| Fatal bleeding (NVAF) | 0.2%/yr vs 0.5%/yr warfarin (ROCKET-AF; HR 0.50) | Any time | Resuscitation; reversal; root-cause review |
| Spinal or epidural haematoma (boxed warning) | Rare; risk increases with neuraxial procedures | Hours to days after neuraxial intervention | Emergency MRI; urgent surgical decompression; can result in permanent paralysis |
| GI bleeding | 0.7%/yr (CAD/PAD) to 2.0%/yr (NVAF) | Any time | Hold drug; endoscopy; treat source; consider PPI prophylaxis on resumption |
| Anticoagulant-related nephropathy (postmarketing) | Rare; underrecognised | Days to weeks; often subacute | Hold drug; investigate haematuria and rising creatinine; nephrology referral if persists |
| Hepatotoxicity (postmarketing: hepatitis, cholestasis, jaundice) | Rare; idiosyncratic | Days to months after initiation | Discontinue; check LFTs and bilirubin; switch to non-DOAC if confirmed |
| Anaphylaxis / angioedema (postmarketing) | Very rare | Minutes to hours | Permanent discontinuation; epinephrine and supportive care; switch to apixaban or VKA |
| Stevens-Johnson syndrome / DRESS (postmarketing) | Very rare | Days to weeks | Permanent discontinuation; dermatology referral; admit if severe |
| Eosinophilic pneumonia (postmarketing) | Very rare | Days to weeks | Discontinue; pulmonology consult; corticosteroids may be required |
| Agranulocytosis, thrombocytopenia (postmarketing) | Rare | Variable | Discontinue; haematology referral; supportive care |
| Recurrent thrombosis after premature discontinuation (boxed warning) | Increased rate observed during transitions | Hours to weeks after stopping | Bridge with parenteral or oral anticoagulant if discontinuation is for non-bleeding reason |
In NVAF, rivaroxaban does not produce more major bleeding overall than well-controlled warfarin (3.6% vs 3.5% per year), but the anatomical pattern is different: fewer intracranial bleeds (HR 0.67) and fewer fatal bleeds (HR 0.50) but more GI bleeds (HR 1.61). This trade-off — less catastrophic but more nuisance bleeding — is a recurring DOAC theme and should shape patient selection. In patients with a history of GI bleeding, apixaban may be a reasonable alternative; in patients with ICH risk factors, rivaroxaban or another DOAC is generally preferred over warfarin.
Drug Interactions
Rivaroxaban is a substrate of both CYP3A4/5 and the P-glycoprotein efflux transporter. Drugs that simultaneously inhibit both pathways significantly increase exposure and bleeding risk; combined inducers reduce exposure and increase thrombotic risk. Coadministration with other antithrombotics (anticoagulants, antiplatelets, NSAIDs, fibrinolytics) is the dominant pharmacodynamic concern. Unlike warfarin, rivaroxaban has no clinically significant interactions with vitamin K–rich foods, gastric pH modulators (PPIs, H2 blockers, antacids), or atorvastatin.
Rivaroxaban requires both CYP3A4 and P-gp for elimination. A drug that inhibits or induces just one pathway typically produces only a modest pharmacokinetic effect. The clinically dangerous interactions are with agents that affect both simultaneously — the “azoles, ritonavir, rifampin, carbamazepine, phenytoin, St. John’s wort” list. This pattern is the same for apixaban; for dabigatran (P-gp only), the risk profile differs.
Monitoring
Routine therapeutic drug monitoring is not required and is not recommended by the FDA prescribing information. Standard coagulation tests (PT, INR, aPTT) are influenced by rivaroxaban but are unreliable for dose titration. The principal monitoring tasks are renal function, bleeding surveillance, and adherence assessment.
-
Bleeding signs & symptoms
Every visit; daily during inpatient
Routine Ask about bruising, epistaxis, gum bleeding, melena, haematuria, menorrhagia. Inspect mucous membranes. Suspect occult bleeding in any post-procedure or anticoagulated patient who becomes hypotensive or develops unexplained anaemia. -
Renal function (eGFR or CrCl)
Baseline; every 6–12 months; sooner if ≥75 years, frail, or unstable
Routine Use Cockcroft-Gault with actual body weight (not eGFR by MDRD or CKD-EPI) for FDA-aligned dose decisions in adults. Cross-check at any acute illness or contrast-imaging event — AKI is a common reason for inadvertent rivaroxaban over-exposure. -
Haemoglobin / haematocrit
Baseline; periodically; with new symptoms
Trigger-based Investigate unexplained anaemia (occult GI loss is the commonest cause). Consider faecal immunochemical testing or endoscopy in patients with progressive iron-deficiency anaemia. -
Liver function (AST, ALT, bilirubin)
Baseline; with new symptoms or jaundice
Trigger-based Postmarketing reports of hepatitis, cholestasis, and jaundice. Avoid initiation in Child-Pugh B or C. Discontinue and switch agents if hepatocellular injury appears drug-related. -
Adherence assessment
Every visit
Routine DOAC adherence is consistently lower than warfarin in real-world data. Use refill records, pill counts, or single-time anti-Xa levels in suspected non-adherence. Once-daily dosing aids compliance for NVAF and extended VTE prevention. -
Bleeding-risk reassessment (HAS-BLED, ORBIT, ATRIA)
Annually; with new comorbidity or medication
Routine Identify modifiable factors (uncontrolled BP, concomitant antiplatelets, alcohol, NSAIDs). Useful for shared decision-making rather than for stopping anticoagulation. -
Anti-factor Xa activity (rivaroxaban-calibrated)
Selected scenarios only
Trigger-based Use cases: active major bleeding, urgent surgery, suspected non-adherence, extreme body weight, dialysis, or breakthrough thrombosis. Not for routine dose adjustment. Plain anti-Xa (heparin-calibrated) underestimates rivaroxaban activity. -
Pregnancy testing
Baseline in females of reproductive potential; with menstrual changes
Routine Discuss contraception and pregnancy planning. Switch to LMWH if pregnancy occurs or is planned. Counsel about menorrhagia risk on rivaroxaban. -
Periodic indication review
At least annually
Routine Confirm ongoing indication, balance benefit/bleeding-risk, and reassess against alternative DOACs (apixaban often preferred in high GI bleeding risk; LMWH preferred in active malignancy with luminal GI tumour).
Discontinue rivaroxaban at least 24 hours before procedures with low-to-moderate bleeding risk. For high bleeding-risk surgery, hold for 48 hours (CrCl ≥30 mL/min) or 72 hours (CrCl <30). For neuraxial procedures, an indwelling epidural catheter should not be removed until at least 2 elimination half-lives have elapsed (~18 h young adults, ~26 h elderly), and the next rivaroxaban dose should not be given until at least 6 hours after catheter removal. Resume rivaroxaban 24 hours postoperatively if haemostasis is established — sooner exposes the patient to surgical-site bleeding, later exposes them to thrombosis.
For life-threatening bleeding, andexanet alfa (Andexxa) is the FDA-approved reversal agent. It is a recombinant modified factor Xa decoy protein that binds rivaroxaban and other factor Xa inhibitors with high affinity, restoring endogenous factor Xa activity. If andexanet alfa is unavailable, 4-factor prothrombin complex concentrate (4F-PCC, e.g. Kcentra) at 25–50 IU/kg has been used off-label. Activated charcoal can be considered within 2 hours of ingestion. Rivaroxaban is highly protein-bound (~92–95%) and is not effectively dialysable. Vitamin K and protamine sulfate are ineffective.
Contraindications & Cautions
Premature discontinuation of any oral anticoagulant, including XARELTO, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from XARELTO to warfarin in clinical trials in atrial fibrillation patients. If XARELTO is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.
Epidural or spinal haematomas have occurred in patients treated with XARELTO who are receiving neuraxial anaesthesia or undergoing spinal puncture. These haematomas may result in long-term or permanent paralysis. Risk factors include indwelling epidural catheters, concomitant use of drugs that affect haemostasis (NSAIDs, platelet inhibitors, other anticoagulants), traumatic or repeated epidural or spinal punctures, and a history of spinal deformity or surgery. Monitor for neurological impairment and treat urgently if observed.
Absolute contraindications (FDA prescribing information, Section 4)
- Active pathological bleeding (e.g., active peptic ulcer haemorrhage, active intracranial haemorrhage, retinal bleeding)
- Severe hypersensitivity reaction to rivaroxaban (e.g., anaphylactic reactions)
Use NOT recommended (per FDA Warnings and Precautions)
- Prosthetic heart valves — including post-TAVR: the GALILEO trial showed higher rates of death and bleeding with rivaroxaban after transcatheter aortic valve replacement. Safety and efficacy have not been studied in patients with other prosthetic heart valves or other valve procedures. Use a vitamin K antagonist for mechanical valves.
- Triple-positive antiphospholipid syndrome (positive lupus anticoagulant, anticardiolipin, and anti-β2-glycoprotein I antibodies): higher rates of recurrent thrombotic events with DOACs vs warfarin. Use a vitamin K antagonist.
- Haemodynamically unstable PE or PE patients who may receive thrombolysis or pulmonary embolectomy: not recommended as initial therapy in place of unfractionated heparin.
- Acutely ill medical patients at high bleeding risk: bronchiectasis or pulmonary cavitation history, active cancer with in-hospital treatment, dual antiplatelet therapy, recent gastroduodenal ulcer or recent bleeding (excluded from the MAGELLAN labelled population).
- CrCl <15 mL/min (other than NVAF in dialysis based on PK modelling) — avoid use in VTE-related and orthopaedic indications.
- Moderate to severe hepatic impairment (Child-Pugh B or C) or any hepatic disease associated with coagulopathy.
Use with caution — specialist input recommended
- Concomitant antiplatelet or NSAID therapy: assess net benefit; minimise duration of triple therapy in AF + PCI
- Body weight >120 kg or BMI >40 kg/m²: limited PK data; ISTH 2021 guidance permits DOAC use for some indications in obesity but with cautions, particularly for treatment-dose VTE
- Active malignancy with luminal GI tumours: some studies (e.g., SELECT-D) suggested higher GI bleeding with DOACs vs LMWH in this subgroup
- Pregnancy: avoid; use LMWH instead
- Lactation: rivaroxaban detected in human milk; weigh benefits against potential infant exposure
- Older adults (≥75 years): bleeding rates are higher in absolute terms; assess fall risk and renal trajectory
- Recent or planned spinal/epidural anaesthesia or lumbar puncture: see boxed warning B; carefully time around half-life
- Frequent falls or significant cognitive impairment: bleeding risk may outweigh thrombotic benefit
- Dual P-gp + moderate CYP3A inhibitors (erythromycin, dronedarone, fluconazole) in CrCl 15–80 mL/min: avoid unless clearly justified
Patient Counselling
Purpose of therapy
Explain that rivaroxaban is a blood-thinning medicine (an anticoagulant) that prevents the blood from forming dangerous clots. Depending on the indication, it is used to prevent strokes in atrial fibrillation, to treat or prevent blood clots in the legs (DVT) or lungs (PE), to prevent clots after major joint surgery, or — at a low dose — to reduce heart attacks, strokes, and limb events in long-standing artery disease. Stopping rivaroxaban without speaking to the prescriber can lead to a stroke or recurrent clot; this is among the most common preventable causes of treatment failure. Patients should never stop on their own.
How to take
The 15 mg and 20 mg tablets must be taken with food (ideally the largest meal of the day) at the same time each day. The 2.5 mg and 10 mg tablets can be taken with or without food. Tablets can be swallowed whole or, if needed, crushed and mixed with applesauce immediately before use. If a once-daily dose is missed, take it as soon as remembered the same day; do not double up. For twice-daily dosing (15 mg BID for acute VTE, or 2.5 mg BID for vascular disease), take a missed dose as soon as possible — for the 15 mg BID, it is acceptable to take both 15 mg tablets together to make up the daily dose, then resume the regular schedule the next day. Bring a current medication list to every appointment. Patients should carry an anticoagulation alert card or wear a medical bracelet.
Sources
- U.S. Food and Drug Administration. XARELTO (rivaroxaban) tablets and oral suspension — Prescribing Information (revised 06/2025). accessdata.fda.gov/drugsatfda_docs/label/2025/022406s044,215859s005lbl.pdf Primary regulatory source for indications, dosing, boxed warnings, contraindications, adverse-reaction frequencies, and interaction studies.
- European Medicines Agency. Xarelto (rivaroxaban) Summary of Product Characteristics. ema.europa.eu/en/medicines/human/EPAR/xarelto European prescribing reference; useful for additional warnings and pharmacovigilance updates.
- FDA Roundup. First generic rivaroxaban (2.5 mg) approval. March 4, 2025. fda.gov/news-events/press-announcements/fda-roundup-march-4-2025 Documents first generic ANDA approvals (Lupin, Taro) for the 2.5 mg vascular dose only; higher doses still under patent at time of writing.
- Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation (ROCKET AF). N Engl J Med. 2011;365(10):883-891. doi.org/10.1056/NEJMoa1009638 Pivotal trial for stroke prevention in NVAF; basis for the 20 mg / 15 mg dose by renal function.
- EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism (EINSTEIN-DVT). N Engl J Med. 2010;363(26):2499-2510. doi.org/10.1056/NEJMoa1007903 Established single-drug oral therapy for acute DVT without parenteral lead-in.
- EINSTEIN-PE Investigators, Büller HR, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-1297. doi.org/10.1056/NEJMoa1113572 Sister trial to EINSTEIN-DVT covering symptomatic PE; same dosing schema.
- Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism (EINSTEIN-CHOICE). N Engl J Med. 2017;376(13):1211-1222. doi.org/10.1056/NEJMoa1700518 Established the 10 mg once-daily dose for extended VTE prevention with similar bleeding to aspirin.
- Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease (COMPASS). N Engl J Med. 2017;377(14):1319-1330. doi.org/10.1056/NEJMoa1709118 Established the 2.5 mg BID + ASA vascular dose for chronic CAD/PAD; 24% relative reduction in CV events (4.1% vs 5.4%) at the cost of more major bleeding (HR 1.8).
- Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization (VOYAGER PAD). N Engl J Med. 2020;382(21):1994-2004. doi.org/10.1056/NEJMoa2000052 Established benefit of vascular dose plus aspirin after lower-extremity revascularisation for symptomatic PAD.
- Cohen AT, Spiro TE, Büller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients (MAGELLAN). N Engl J Med. 2013;368(6):513-523. doi.org/10.1056/NEJMoa1111096 Basis for extended VTE prophylaxis indication in medically ill patients (with high-bleeding-risk subgroups now excluded from labelling).
- Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty (RECORD1). N Engl J Med. 2008;358(26):2765-2775. doi.org/10.1056/NEJMoa0800374 First of three RECORD trials supporting orthopaedic VTE prophylaxis at 10 mg daily.
- Male C, Lensing AWA, Palumbo JS, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children (EINSTEIN Junior). Lancet Haematol. 2020;7(1):e18-e27. doi.org/10.1016/S2352-3026(19)30219-4 Paediatric pivotal trial supporting weight-based dosing in children with acute VTE.
- McCrindle BW, Michelson AD, Van Bergen AH, et al. Thromboprophylaxis for children post-Fontan procedure (UNIVERSE). J Am Heart Assoc. 2021;10(22):e021765. doi.org/10.1161/JAHA.120.021765 Paediatric trial supporting rivaroxaban for thromboprophylaxis after Fontan surgery.
- Dangas GD, Tijssen JGP, Wohrle J, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement (GALILEO). N Engl J Med. 2020;382(2):120-129. doi.org/10.1056/NEJMoa1911425 Negative trial — basis for the recommendation against rivaroxaban after TAVR.
- Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. J Am Coll Cardiol. 2024;83(1):109-279. doi.org/10.1016/j.jacc.2023.08.017 Current US recommendations on stroke prevention in NVAF, including DOAC selection.
- Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021;160(6):e545-e608. doi.org/10.1016/j.chest.2021.07.055 CHEST guideline endorsing DOACs as first-line for most VTE; weight-based and renal considerations.
- Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2020;41(4):543-603. doi.org/10.1093/eurheartj/ehz405 European recommendations for acute and extended PE management with rivaroxaban and other DOACs.
- Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927-974. doi.org/10.1182/bloodadvances.2020003442 ASH guidance on cancer-associated thrombosis — supports DOACs (including rivaroxaban) in selected cancer patients.
- Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53(1):1-16. doi.org/10.1007/s40262-013-0100-7 Comprehensive PK/PD review including renal-impairment data, food effect, and elderly pharmacokinetics; source for CYP3A4 18%, CYP2J2 14%, hydrolysis 14%.
- Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76(3):455-466. doi.org/10.1111/bcp.12075 Source for verified interaction magnitudes: ketoconazole AUC +158%, ritonavir +153%, clarithromycin +54%, erythromycin +34%.
- Connolly SJ, Crowther M, Eikelboom JW, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors (ANNEXA-4). N Engl J Med. 2019;380(14):1326-1335. doi.org/10.1056/NEJMoa1814051 Pivotal data supporting andexanet alfa as the FDA-approved reversal agent for rivaroxaban-associated major bleeding.
- Martin K, Beyer-Westendorf J, Davidson BL, et al. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC. J Thromb Haemost. 2021;19(8):1874-1882. doi.org/10.1111/jth.15358 ISTH guidance on DOAC use in obesity; informs body-weight cautions for rivaroxaban.